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Abstract: Introduction: Andropause is a syndrome with a slow progression that is associated with androgen deficiency
in older men. This study aimed to collect all scientific data about the factors that cause the occurrence of an-
dropause in Iranian men as well as the aspects of life which can be affected by this disorder. Materials and
Methods: Searching was conducted in international databases including MedLine, Scopus, Web of Science, Pro-
Quest, and national database (SID) from inception until December 2019. Retrieved studies were reviewed by
two researchers independently and selected studies were summarized in a table. Results: Finally, 21 related
studies were included and summarized information showed that andropause can be negatively affected by age,
lower testosterone levels, smoking, lower economic status, lower educational level, and poor employment sta-
tus. Some studies have also implied that there is a significant correlation between andropause and quality of
life, sleep quality, depression, anxiety, marital dissatisfaction, urinary incontinence, coronary heart disease, and
metabolic syndrome. Conclusion: According to the collected data in this present study, Iranian studies have
covered a wide variety of complications and related factors in the field of andropause but, we still lake some
studies about other aspects of andropause such as musculoskeletal impairment, erectile dysfunction, memory
and cognitive disorders, skin and hair disorders, decreased libido, and other mood disorders.
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1. Introduction
Andropause is a series of geriatric procedures that is phys-
ically pretty similar to menopause in women and occurs in
ages above 45. The amount of protein attaching to male sex
hormone (SHBG) increased in middle ages men, which re-
duces free testosterone [1]. This procedure sometimes oc-
curs prematurely for reasons other than the normal aging
process such as cardiovascular diseases, long-term use of
some medications, stress, depression, poor sleep quality, di-
abetes, metabolic syndromes, obesity, and alcoholism, all of
which impact testosterone production [1].
∗Corresponding Author: Ehsan Shojaeefar; Address: Men’s Health and Re-
productive Health Research Center, Shahid Beheshti University of Medi-
cal Sciences, Tehran, Iran. Email: E.Shojaeefar@yahoo.com, Phone: (+98)
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Contrary to women’s menopause, men do not face infertility
in andropause; however, their success in fertility drops sig-
nificantly. The most prevalent signs of andropause in the lit-
erature are fatigue, impatience, depression, anger, increased
irritability, reduced sexual activity, reduced muscle mass,
flushing, memory impairment, nocturia, hair loss, constipa-
tion, and bone pain [2]. This syndrome has a slow progres-
sion that is associated with androgen deficiency in older men
(age > 50 years) [3, 4]. There are several terms for this syn-
drome including male menopause, androclise, androgen de-
cline in the aging male (ADAM), aging male syndrome (AMS),
late-onset hypogonadism (LOH) [5]. Andropause can also
occur in men who have lost their sexual function, due to ac-
cidents or advanced prostate treatment. The rate of decrease
in testosterone levels varies in different peoples. Decreased
testosterone or sperm production is related to male hypogo-
nadism [6, 7] which is caused by androgen deficiency and can
adversely affect multiple organ function and quality of life [6,
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8].
Serum testosterone levels decrease with aging in men at
a rate of 1% per year. This decrease is associated with
changes in body function, declined physical energy, and
muscle strength. Andropause is characterized by the follow-
ing symptoms such as nervousness, reduced potency and li-
bido, fatigue, depression, memory, and sleep problems [9].
Ninety-eight percent of testosterone in plasma is combined
with proteins (65% to sex hormone-binding globulin (SHBG)
and 33% to albumin) [2] and only 2% of testosterone is free in
serum. Smoking, obesity, alcohol use, lifestyle, and various
chronic illness are the factors that can be effective in testos-
terone decline [10, 11]. Obesity reduces the total testosterone
and SHBG levels [11]. Job stress is a major factor related to
andropause symptoms for male workers. Studies indicated
that a high level of job stress is associated with andropause
symptoms in men [2].
Decreased free testosterone level is the least concerning is-
sue among all parameters. Andropause without testosterone
deficiency has also been reported in men so the causes of an-
dropause are not clear [12]. We focused on this topic to figure
out all effective factors in the occurrence of andropause and
also to know how andropause affects aspects of Iranian men’s
life and health and also to show where we have the research
gap comparing to the studies from around the world.
2. Material and Methods
This study aimed to collect all scientific data about factors
that cause the occurrence of andropause in Iranian men as
well as aspects of life that can be affected by this disor-
der. Accordingly, this selected title was considered to in-
clude all types of studies (cross-sectional, prospective, and
Cohort studies, etc.) reporting factors and outcomes of
andropause in the Iranian male population. Considering
the following keywords: “Andropause”, “male menopause”,
“Testosterone deficiency”, “late-onset hypogonadism”, “hy-
pogonadism” and “Iran”, electronic searching was conducted
in international databases including MedLine, Scopus, Web
of Science, ProQuest, and national scientific information
database (SID) from inception until December 2019. No
language restriction defined and eligible studies could have
been published in either English or Farsi. Exclusion crite-
ria were non-Iranian participants and studies about knowl-
edge and attitude in this field and also if the testosterone de-
ficiency had a congenital origin. The Process of selecting ar-
ticles completed by two independent researchers. Extracted
data entered into a table which included bibliographic infor-
mation of studies (author‘s name, publication year), study
type and design (participants, conducted tests or question-
naire, intervention, grouping and follow up duration), and
the main study achievements about factors involved in and
affected by andropause. Due to the wide variety of reported
data across studies, the meta-analysis was not applicable.
Finally, the overall statements of the included studies were
compared and discussed to obtain a comprehensive conclu-
sion.
3. Results
At the initial searching phase, 243 articles were retrieved. the
Screening was initially done on study titles which led to the
exclusion of 195 articles. Additional 27 articles were excluded
due to studying different target groups, non-Iranian, knowl-
edge, and attitude about andropause and also if they were
not original studies or no full text available. Finally, 21 orig-
inal studies met the inclusion criteria for this systematic re-
view (Figure 1).
Based on reviewed studies which were summarized in table
1, several factors contribute to the occurrence of andropause
including age, lower testosterone levels, smoking, lower eco-
nomic status, lower educational level, and poor employment
status. There were also some data about factors that af-
fect the gonadal function and cause hypogonadism including
age, HIV, thalassemia, radiotherapy, hypertension, smoking,
methadone therapy, and higher duration of diabetes (Table
2).
Some studies have also implied that there is a significant cor-
relation between andropause and quality of life, sleep quality,
depression, anxiety, marital dissatisfaction, urinary incon-
tinence, coronary heart disease, and metabolic syndrome.
Some studies also demonstrated the correlation of hypog-
onadism or gonadal dysfunction with BMI, prolactin, de-
pression, FBS, HA1C, hyperlipidemia, waist circumference,
hemoglobin, and LH (Table 3).
There were only three interventions that reported significant
improvement of the andropause symptoms using testos-
terone replacement therapy (TRT) and an educational pack-
age.
4. Discussion
Given the title of the present study which indicates that it
aims to study andropause in Iranian men as well as its rea-
sons and consequences, we will also proceed to study the
clinical symptoms of andropause syndrome. According to
a holistic study, these consequences can be divided into the
following main categories:
1. Physical consequences such as abdominal obesity, re-
duced muscle mass, reduced mineral density in bones, de-
creased body hair, and changes in skin
2. Mental consequences including depression, impairment
of the cognitive function monitoring center, and increased
tiredness
3. Sexual function consequences such as reduced sexual
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drive, reduced sexual function quality, and erectile dysfunc-
tion [24]
Clear signs of men entering their andropause period mani-
fest in the older male population. A Korean review study re-
ported that 64.4% of men aged 45 to 70 might suffer from an-
dropause syndrome, the most prevalent symptom of which
is erectile dysfunction which manifests in 71% of cases and
has the highest share among other symptoms. This study
also pointed out that andropause is a biochemical clinical
syndrome depending on age which manifests due to testos-
terone shortage, and patients experience a considerable drop
in the quality of life as well as complications in bones, fat
tissue, muscles, brain, and hematopoiesis mechanisms. In
this regard, decreased testosterone in men aged over 50 gen-
erally resulted in symptoms such as lack of concentration,
nervousness, memory impairment, depression, sleep depri-
vation, low energy, a general feeling of sickness, reduced li-
bido, erectile dysfunction, Joint and bone pain, lower general
strength, increased BMI, and obesity [25].
Another study considered erectile dysfunction to be the most
important complication due to andropause, which was ob-
served in 38% of the study population [26] The authors of this
review suggested to assess erectile dysfunction prevalence in
Iranian men and also in the subgroup of late-onset hypogo-
nadism in more epidemiologic studies.
Akmal Taher conducted a study on 501 people aged 40 to 90.
The author examined participant’s primary data such as age,
education, occupation, income, marital status, and sexual re-
lationships to diagnose andropause and its intensity, and re-
ported that 153 people out of the 499 participants suffered
from andropause that is equal to 70.94% of the study popula-
tion [27].
In a study, from 193 participants (54%) suffered from mild an-
dropause, 138 participants (38%) suffered from moderate an-
dropause, and only 23 participants (6.5%) suffered from se-
vere andropause. It was also evident that andropause preva-
lence had a positive relationship with age [28]. This finding is
similar to our endemic data.
Another population study focused on the manifestation of
andropause reported symptoms such as mood disorders,
nervous irritability, severe depression, memory impairment,
severe fatigue, stress management failure, and a feeling of
disgust towards activities that used to be pleasurable for the
patient [29] This study indicated that 42% of the participants
suffered from depression and its relevant disorders. Other
participants experienced mood disorders. Psychologists be-
lieve that andropause is a period when men comprehend
their lives as a whole and not as a series of their actions, and
tend to experience a sense of underdevelopment [30]. These
data are consistent with our national documents but more
detailed statistics are needed.
A study conducted by Bechtz et al. in terms of admission cri-
teria revealed the following: reduced libido in 91% of partici-
pants, a low energy level in 89%, erectile dysfunction in 77%,
severe memory impairment in 77%, hair loss in 70%, irritabil-
ity in 68%, reduced endurance in 66%, and performance dys-
function in 51% of men. They also showed that 21% of men
aged 55-59, 26% of men aged 60-69, and 31% of men aged 70-
89 suffered from reduced testosterone levels [31].
Another review pointed out that reduced testosterone lev-
els accompanied decreased libido in 12%, erectile dysfunc-
tion in 16%, and osteoporosis in 1% of men. This review re-
vealed that Middle-aged men experience a variety of symp-
toms, such as sexual and erectile dysfunction, reduced libido,
poor sleep quality, mood swings, and low motivation. The
reduced hormone concentration is gradual so the symptoms
manifest gradually as well [32].
A report published in the New England Journal of Medicine
offers other viewpoints. A biochemical, clinical experiment
conducted on 3,369 men aged 40-79 indicated that symp-
toms such as sexual manifestations including a lower num-
ber of sexual intercourse and impaired ability to engage in
strenuous activity such as running, lifting heavy objects, per-
forming heavy physical exercises, walking more than 10 km,
bending on the knee, and psychological symptoms such as
low energy, sadness, grief, and fatigue have no significant
relationship, while symptoms such as changes in sleep pat-
terns, concentration loss, feeling worthless, nervousness,
anxiety, and difficulty getting up from the sitting position are
associated with andropause [33]. Our results showed a corre-
lation of andropause with sleep quality and anxiety too.
Another study also points out that testosterone decreases by
1% as a result of aging, and the reduced testosterone level is
more pronounced due to the globulin attached to the sexual
hormone The extent of hormonal changes is different from
person to person and can be associated with various factors
such as diseases, obesity, and medication. Reduced testos-
terone concentration might result in impaired memory, ver-
bal function, and visual function, and might impact multi-
ple other functions such as a wide range of mood disorders,
metabolic disorders, osteoporosis, and cognitive decline [34].
5. Conclusion
According to the collected data in this present study, it is rec-
ommended to conduct more comprehensive studies about
causes and complications caused by andropause in middle-
aged men that didn’t mention in Iranian studies. Indeed, Ira-
nian studies have covered a wide variety of complications
and related factors in the field of andropause but, we still
lake some studies about other aspects of andropause such as
musculoskeletal impairment, erectile dysfunction, memory
and cognitive disorders, skin and hair disorders, decreased
libido, and other mood disorders.
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Table 1: Summary of included studies about factors that affect or affected by andropause. (Continuous)
First Author [reference] Study design (questionnaire,
intervention, sample size, age,
place)
Study type Maine finding
Najafabady, 2013 [3] ADAM and serum levels of free
and total testosterone in 90
male, >40 y, university staffs
cross-sectional No significant relationship be-
tween participants with and
without andropause symptoms
regarding age, BMI, blood pres-
sure, income or free and total
testosterone
Sofimajidpour, 2015 [5] ADAM and serum testosterone
in 80 men, >50 y, before and af-
ter daily 40mg testosterone for 6
m
Before-after study. Significant decrease in an-
dropaused men form 100% to
87.5, 55 and 0 at baseline, 1,
3, 6 months after treatment
respectively
Afsharnia, 2016 [10] SF-36 & AMS in 80 men, 40-60 y,
TUMS staff.
Cross-sectional Andropause causes low QOL
and there was a significant
relationship between age and
Andropause
Hakimi,2019[13] Socio-demographic & MASSQ in
264 andropausal men, mean age
58.8, Tabriz.
Cross-sectional Unemployment, retirement,
marital dissatisfaction, being a
tenant, and having no academic
education were predictors of
severe andropause symptoms.
Khosravi,2014[4] AMS & PHQ-2 and 9 were used
to screen depression & MET
& multi-sectoral (about demo-
graphic and fertility) in 521 men,
45-65y from blood donation or-
ganization
Cross-sectional There was significant correla-
tion between depression and an-
dropause (r=0.48)
Mousavi,2018[11] Socio-demographic and health
status & MASSQ & SF-12 in 393
men, 40-85 y, urban health care
center in Ilam
Cross-sectional Men with higher andropausal
symptoms had lower QOL, pre-
dictors of andropause were:
higher age, lower education, de-
pression, coronary heart disease,
and urinary incontinence
Mousavi,2018[14] ADAM in 600men 40-65y, health
centers in Arak
Cross-sectional There was a significant rela-
tionship between age and An-
dropause and sexual life quality
AliAkbari,2019[15] Socio-demographic (GHQ) and
ADAM & psychological health in
patients with psychology sign of
andropause and patients with
the clinical diagnosis of an-
dropause in 150 men, 45-65y,
staff of TUMS.
Casual-comparative Patients with laboratory diagno-
sis of andropause had severe de-
pression and anxiety
Samipoor,2017[16] Demographic & AMS, 140men,
>40 y, health center in Rasht
Cross-sectional Men over age 40 had experi-
enced symptoms of andropause,
there is a significant positive cor-
relation between BMI and An-
dropause.
Madani ,2011[9] Demographic, history of drug
usage, history of surgeries
and history of neurologic,
psychogenic, endocrine, cardio-
vascular and urologic diseases
& NCEP-ATP III criteria (for
metabolic syndrome) & Morning
serum FT in 241men with ED,
mean age 50
The relative frequency of
metabolic syndrome and testos-
terone deficiency in men with
ED seems to be significant and
it can cause cardiovascular dis-
ease. So ED can be a sign of a
need for medical intervention.
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Table 1: Summary of included studies about factors that affect or affected by andropause. (Continuous)
First Author [reference] Study design (questionnaire,
intervention, sample size, age,
place)
Study type Maine finding
Afsharnia 2017[8] SF-36 & AMS in 80 men, 40-60y,
TUMS stuffs.
Quasi-experimental The computer-based educa-
tional package has a positive
effect on QOL and reduction of
hypogonadism symptoms
Afsharnia 2019[6] A demographic questionnaire
and then the AMS & diagnosis of
male hypogonadism by the urol-
ogist in 80men 40-60y, TUMS
stuffs.
Cross-sectional There was a significant associ-
ation between age and sever-
ity of hypogonadism and also
between the economic status,
cigarette consumption, hours of
sleep, and the severity of hypog-
onadism symptoms.
Ahmadloo,2010[17] Pelvic radiotherapy 50-Gy ra-
diation & 2Gy per fraction
5days a week and 5-FU-based
chemotherapy & testis dosime-
try twice during study & blood
samples for LH, FSH, and
Testosterone were taken 3 times:
before, during and 4 to 6 week
after study in 40 men with Rectal
adenocarcinoma, Mean age 58.
Cross-sectional There was a significant increase
of FSH, LH, and decrease of
Testosterone after radiation and
risk for testicular damage, hy-
pogonadism, and infertility
Aminilari,2012[12] Socio-demographic & BMSFI
(for assessing sexual function) &
Beck Depression Inventory-II &
blood sample for total and free
testosterone in 278 men with
HIV, mean age 37y
Cross-sectional 68% had hypogonadism, 74%
minimal and 68% moderate to
severe depression and they have
low levels of testosterone. There
was a direct association between
depression and gonadal func-
tion. There was a negative as-
sociation between gonadal func-
tion and methadone therapy
Faramarzia,2014[18] Socio-demographic & morning
serum for FT, TT, LH, FSH, and
prolactin in 278 men with HIV
positive mean age 37 y
Cross-sectional The prevalence of hypogo-
nadism in HIV positive patients
was high (62.8% based on FT).
hypogonadism was positively
associated to PRL (OR: 1.18), age
and methadone use (OR:1.47)
and negatively with BMI (0.88),
LH (OR = 0.91), HGB (OR =
0.788). but had no significant as-
sociation with HAART, smoking,
hepatitis or reaching the AIDS
stage.
Heydari 2014[7] IIEF & TT, LH, PRL and TSH
(only if LH was low) before and
3 W after TRT (A single dose of
250 mg (IM) testosterone), in 48
men with ED and LOH symp-
toms, mean age 53
Quasi-experimental 94% of patients got a significant
improvement in libido, QOL,
and IIEF. LH decreased signifi-
cantly after TRT, but the testos-
terone level had no change.
Karimi,2012[19] LH, FSH, PRL, testosterone, and
estradiol in 75 men with Beta-
Thalassemia under treatment of
HU 8-15mg/kg/day at least 5
years, in comparison with 31
patients without HU. mean age
22.7, in southern Iran.
Case-control There was no significant differ-
ence in the level of gonadal hor-
mone between patients with or
without HU.
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Table 1: Summary of included studies about factors that affect or affected by andropause.
First Author [reference] Study design (questionnaire,
intervention, sample size, age,
place)
Study type Maine finding
Mirzaei,2012[20] TT & SHBG & ADAM in 325 dia-
betics men >30 y, Isfahan
Cross-sectional Based on TT and cBT Prevalence
of borderline hypogonadism
was 9.9% and 36%, respectively.
TT was negatively correlated
with BMI and triglyceride. Hy-
pogonadism (TT ≤12 nmol/l)
was not correlated with obe-
sity, smoking, age, duration of
diabetes, blood pressure, and
HbA1c.
Sadat Hosseini,2019[21] ADAM & FT & demographic &
lipid and glycemic control &
BMI, blood pressure & SF-36 in
2 groups (67 diabetes men with-
out hypogonadism and 93 dia-
betes men with hypogonadism,
mean age 53-59
Case- control Dyslipidemia, FBS and HbA1c,
waist circumference and, BMI
were significantly higher and
QOL was lower in hypogonadal
patients compared with patients
without hypogonadism.
Samipoor 2017[22] AMS & FT & TT& FSH & LH
in140 men >40y, GUMS
Cross-sectional 73% of men had LOH symptoms
among them 3.8% had low FT
and 33% had low borderline TT.
The LH and FSH levels increased
with age. There was a significant
association between LOH score
>34 with age (OR:1.05), BMI (OR:
1.15), smoking (OR: 2.2). Self-
employed (OR:4.38) and em-
ployees (OR: 3.14) had higher
odds in comparison with work-
ers.
Sayehmiri,2016[23] 16 document about the preva-
lence of Hypogonadism in Tha-
lassemic patients, Mean age 17
Meta-analysis There was a high prevalence
of hypogonadism (49%) in
men with Thalassemia Major.
The highest prevalence was
in Bushehr and the lowest in
Zanjan
ADAM: Androgen Decline in the Aging Male, TUMS: Tehran University of Medical Science, AMS: Aging Male Scales,
y: year, M: month. MASSQ: male andropause symptoms self-assessment questionnaire. PHQ: Patient Health Questionnaires,
MET: Metabolic Equivalent of Task, SF-12: 12-item Short Form Health Survey,
NCEP-ATPIII: National Cholesterol Education Program- Adult Treatment Panel III, ED: erectile dysfunction,
SF-36: 36-item short form health survey, QOL: Quality of life, Gy: Gray, FU: Fluorouracil,
LH: Luteinizing Hormone, FSH: Follicle-Stimulating Hormone, BMSFI: Brief Male Sexual Function Inventory,
TT: Total testosterone, FT: free testosterone, HGB: Hemoglobin, PRL: Prolactin, HAART: highly active antiretroviral therapy,
AIDS: Acquired immunodeficiency virus, TSH: Thyroid stimulating hormone, IIEF: International Index of Erectile Function,
TRT: testosterone replacement therapy, LOH: late-onset hypogonadism, HU: Hydroxyurea,
cBT: Calculated bioavailability of testosterone. LDL: Low-density lipoprotein, BMI: Body mass index,
SHBG: Sex hormone binding globulin, GUMS: Guilan University of Medical Science,
GHQ: General health questionnaire, HbA1c: Hemoglobin A1C, FBS: Fasting Blood Sugar.
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Table 2: Factors that contribute to the occurrence of andropause or affects the gonadal function.
The number of studies mentioned significant (+) or no significant (–) effect
Factor Andropause or LOH Hypogonadism or gonadal dysfunction
Age + + + + + + – + + +
Lower Testosterone level + + + + – NR
Smoking + + + –
Lower economic status + + – NR
Lower educational level + + NR
Poor employment status + + + NR





Higher duration of diabetes NR +





Table 3: Factors that have correlation with andropause or hypogonadism.
Factor Number of studies mentioned positive (+) or negative (–) correlation
Andropaus or LOH Hypogonadism or gonadal dysfunction
Quality of life – – – –
Sleep quality – NR
BMI + + – + +
Depression + + +
Anxiety + NR
marital dissatisfaction + + NR
urinary incontinence + NR
coronary heart disease + NR





Waist circumference NR +
Hemoglobin NR –
LH NR –
BMI: Body Mass Index
FBS: Fasting Blood Sugar
LH: Luteinizing Hormone
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Figure 1: PRISMA Flow diagram of studies on factors involved in and affected by Andropause in Iranian men.
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